ErbB and Insulin Receptor Signaling Pathways (ErbB/IR Pathways)

The ErbB and Insulin Receptor signaling pathways are critical networks of receptor tyrosine kinases (RTKs) that govern cellular growth, metabolism, and survival. The ErbB family, including EGFR and HER2, is a primary driver of oncogenesis when mutated or overexpressed, while the Insulin Receptor (IR) and Insulin-like Growth Factor 1 Receptor (IGF-1R) are central to metabolic regulation and growth [Lemmon & Schlessinger, 2010, Cell]. These pathways exhibit extensive crosstalk, where activation of one can compensate for the inhibition of the other, often leading to drug resistance in cancer therapy [Nahta et al., 2005, Cancer Research]. For example, IGF-1R signaling can bypass HER2 inhibition in breast cancer, necessitating dual-targeting strategies. Therapeutic interventions include monoclonal antibodies like Trastuzumab and small-molecule inhibitors like Erlotinib, alongside metabolic agents like Metformin [Belfiore et al., 2009, Endocrine Reviews]. Understanding the integration of these pathways is essential for developing effective treatments for both metabolic diseases and various malignancies [UniProt, 2024].

Other names

EGFR/Insulin signaling crosstalkErbB-IGF1R axisRTK signaling networkErbB and Insulin Receptor signaling pathways

Inhibition of receptor tyrosine kinase phosphorylation, competitive binding to extracellular domains, and modulation of downstream PI3K/AKT and MAPK signaling cascades.